NBY vs. NRSN, BGXX, HCWB, AIM, IMNN, CRVO, HOTH, FLGC, CSCI, and WENA
Should you be buying NovaBay Pharmaceuticals stock or one of its competitors? The main competitors of NovaBay Pharmaceuticals include NeuroSense Therapeutics (NRSN), Bright Green (BGXX), HCW Biologics (HCWB), AIM ImmunoTech (AIM), Imunon (IMNN), CervoMed (CRVO), Hoth Therapeutics (HOTH), Flora Growth (FLGC), COSCIENS Biopharma (CSCI), and ANEW Medical (WENA). These companies are all part of the "pharmaceutical products" industry.
NovaBay Pharmaceuticals vs.
NovaBay Pharmaceuticals (NYSE:NBY) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.
NovaBay Pharmaceuticals has higher revenue and earnings than NeuroSense Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than NovaBay Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NeuroSense Therapeutics received 1 more outperform votes than NovaBay Pharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave NeuroSense Therapeutics an outperform vote while only 1.89% of users gave NovaBay Pharmaceuticals an outperform vote.
NovaBay Pharmaceuticals presently has a consensus price target of $0.85, indicating a potential upside of 19.52%. Given NovaBay Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe NovaBay Pharmaceuticals is more favorable than NeuroSense Therapeutics.
NovaBay Pharmaceuticals has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, NeuroSense Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
23.3% of NovaBay Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of NeuroSense Therapeutics shares are held by institutional investors. 0.1% of NovaBay Pharmaceuticals shares are held by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
NeuroSense Therapeutics has a net margin of 0.00% compared to NovaBay Pharmaceuticals' net margin of -102.72%. NeuroSense Therapeutics' return on equity of 0.00% beat NovaBay Pharmaceuticals' return on equity.
In the previous week, NovaBay Pharmaceuticals had 1 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 1 mentions for NovaBay Pharmaceuticals and 0 mentions for NeuroSense Therapeutics. NovaBay Pharmaceuticals' average media sentiment score of 0.00 equaled NeuroSense Therapeutics'average media sentiment score.
Summary
NovaBay Pharmaceuticals beats NeuroSense Therapeutics on 9 of the 16 factors compared between the two stocks.
Get NovaBay Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for NBY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NovaBay Pharmaceuticals Competitors List
Related Companies and Tools
This page (NYSE:NBY) was last updated on 1/22/2025 by MarketBeat.com Staff
